Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minn.
Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minn.
J Thorac Cardiovasc Surg. 2022 Aug;164(2):493-501.e1. doi: 10.1016/j.jtcvs.2020.09.070. Epub 2020 Sep 22.
Retention of the native aortic valve when performing aortic root surgery for aneurysmal disease has become a more common priority. We reviewed our experience in valve-sparing aortic root replacement (VSARR) to evaluate the long-term outcomes and the risk factors for reoperation.
From January 1994 through June 2017, 342 patients (mean age 47.8 ± 15.5 years, 253 [74%] male) underwent VSARR. The most common etiologies were connective tissue disease (n = 143, 42%) followed by degenerative aortic aneurysm (n = 131, 38%). Aortic regurgitation (moderate or greater) was present in 35% (n = 119).
Reimplantation technique was used in 90% patients (n = 308). Valsalva graft was used in 38% patients (n = 131) and additional cusp repair was done in 15% (n = 50). Operative mortality was 1% (n = 5). The median follow-up time was 8.79 years (interquartile range, 4.08-13.51). The cumulative incidence of reoperation (while accounting for the competing risk of death) was 8.4%, 12.8%, and 17.1% at 5, 10, and 15 years, respectively. There were no differences in survival and incidence of reoperation between root reimplantation and remodeling. Larger preoperative annulus diameter was associated with greater risk of reoperation (hazard ratio, 1.10; 95% confidence interval, 1.02-1.19, P = .01). The estimated probability of developing severe aortic regurgitation after VSARR was 8% at 10 years postoperatively. Operative mortality, residual aortic regurgitation at dismissal, and survival improved in recent times with more experience.
VSARR is a viable and safe option with good long-term outcomes and low rates of late aortic valve replacement. Dilated annulus preoperatively was associated with early repair failure.
在进行主动脉根部手术治疗动脉瘤疾病时保留原生主动脉瓣已成为更为常见的重点。我们回顾了在保留主动脉瓣的主动脉根部置换术(VSARR)中的经验,以评估长期结果和再次手术的风险因素。
从 1994 年 1 月至 2017 年 6 月,342 名患者(平均年龄 47.8±15.5 岁,253[74%]名男性)接受了 VSARR。最常见的病因是结缔组织疾病(n=143,42%),其次是退行性主动脉瘤(n=131,38%)。35%(n=119)的患者存在中度或更严重的主动脉瓣反流。
90%的患者(n=308)采用再植入技术。38%的患者(n=131)使用瓦萨尔瓦氏移植物,15%的患者(n=50)进行了额外的瓣叶修复。手术死亡率为 1%(n=5)。中位随访时间为 8.79 年(四分位距,4.08-13.51)。考虑到死亡的竞争风险,再手术的累积发生率分别为 5 年时 8.4%、10 年时 12.8%和 15 年时 17.1%。再植入组和成形术组之间的生存率和再手术发生率没有差异。较大的术前瓣环直径与再手术风险增加相关(风险比,1.10;95%置信区间,1.02-1.19,P=.01)。VSARR 后 10 年发生严重主动脉瓣反流的估计概率为 8%。随着经验的增加,手术死亡率、出院时残留的主动脉瓣反流和生存率都得到了改善。
VSARR 是一种可行且安全的选择,具有良好的长期结果和较低的晚期主动脉瓣置换率。术前瓣环扩张与早期修复失败有关。